leadf
logo-loader
viewAntibe Therapeutics Inc

Antibe Therapeutics unveils $25M bought deal offering to fund non-addictive analgesic drug pipeline

The company, which develops non-addictive medicines for pain and inflammation, is offering 62.5 million units at a price of $0.40 per unit

Canadian money
The proceeds are expected to fund the Phase 3 program for ATB-346, for business development activities and for advancing the other drugs in the company’s pipeline

Antibe Therapeutics Inc (CVE:ATE) has reached a bought deal financing agreement worth $25 million to advance its anti-inflammatory drug ATB-346 and others in its pipeline. 

The Toronto-based company, which develops non-addictive medicines for pain and inflammation, agreed to offer 62.5 million units at a price of $0.40 per unit. Each unit contains one common share and one-third of a share purchase warrant, and whole warrants are exercisable at $0.60 for a period of 24 months.

The syndicate of underwriters led by Bloom Burton Securities Inc will have the option for 30 days after the offering closes to acquire additional units equal to 15% of the total units sold and/or additional warrants by the same metric.

READ: Antibe Therapeutics unveils positive topline results from Phase 2B clinical trial of ATB-346 for osteoarthritis pain

If the underwriters take Antibe up on it, the offering would jump to more than $28.7 million.

The proceeds are expected to fund the Phase 3 program for ATB-346, for business development activities and for advancing the other drugs in the company’s pipeline, including its non-addictive pain reliever ATB-352.

Contact Andrew Kessel at andrew.kessel@proactiveinvestors.com

Follow him on Twitter @andrew_kessel

Quick facts: Antibe Therapeutics Inc

Price: 0.35 CAD

TSX-V:ATE
Market: TSX-V
Market Cap: $134.91 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Antibe Therapeutics Inc named herein, including the promotion by the Company of Antibe Therapeutics Inc in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Antibe Therapeutics releases data from company’s Phase II placebo-controlled...

Antibe Therapeutics (CVE: ATE) CEO Dan Legault joined Steve Darling from Proactive Vancouver with new results from the company’s analysis of primary and secondary data from ATB-346’s recent placebo-controlled efficacy trial. Legault shares the data with Proactive and he also maps out the...

on 12/8/20

2 min read